Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
BriaCell Therapeutics Corp has a consensus price target of $15 based on the ratings of 1 analysts. The high is $15 issued by HC Wainwright & Co. on September 19, 2024. The low is $15 issued by HC Wainwright & Co. on September 19, 2024. The 3 most-recent analyst ratings were released by HC Wainwright & Co. on September 19, 2024, September 11, 2024, and June 4, 2024, respectively. With an average price target of $17 between HC Wainwright & Co., there's an implied 2864.25% upside for BriaCell Therapeutics Corp from these most-recent analyst ratings.
1calculated from analyst ratings
The latest price target for BriaCell Therapeutics (NASDAQ:BCTX) was reported by HC Wainwright & Co. on September 19, 2024. The analyst firm set a price target for $15.00 expecting BCTX to rise to within 12 months (a possible 2515.52% upside). 6 analyst firms have reported ratings in the last year.
The latest analyst rating for BriaCell Therapeutics (NASDAQ:BCTX) was provided by HC Wainwright & Co., and BriaCell Therapeutics maintained their buy rating.
There is no last upgrade for BriaCell Therapeutics
There is no last downgrade for BriaCell Therapeutics.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BriaCell Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BriaCell Therapeutics was filed on September 19, 2024 so you should expect the next rating to be made available sometime around September 19, 2025.
While ratings are subjective and will change, the latest BriaCell Therapeutics (BCTX) rating was a maintained with a price target of $18.00 to $15.00. The current price BriaCell Therapeutics (BCTX) is trading at is $0.57, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.